Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $45,276.48 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,194 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the sale, the executive vice president now directly owns 33,713 shares in the company, valued at approximately $1,278,396.96. The trade was a 3.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Eric Swayze also recently made the following trade(s):

• On Wednesday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $38.31, for a total transaction of $2,030.43.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $34.34 on Friday. The stock has a fifty day moving average price of $39.62 and a 200 day moving average price of $42.76. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a 12-month low of $34.24 and a 12-month high of $54.44.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IONS. The Goldman Sachs Group boosted their price objective on shares of Ionis Pharmaceuticals from $33.00 to $37.00 and gave the company a “sell” rating in a research report on Friday, August 2nd. Wells Fargo & Company cut their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a report on Thursday, November 7th. Leerink Partners upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $53.00 to $62.00 in a report on Wednesday, July 24th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. Finally, Barclays raised their price target on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $60.65.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Great Point Partners LLC acquired a new position in Ionis Pharmaceuticals during the 2nd quarter worth approximately $15,728,000. International Assets Investment Management LLC raised its stake in shares of Ionis Pharmaceuticals by 3,287.0% during the third quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock valued at $13,171,000 after purchasing an additional 319,065 shares during the period. Logos Global Management LP acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth $14,298,000. Zimmer Partners LP purchased a new position in shares of Ionis Pharmaceuticals in the first quarter valued at $11,718,000. Finally, Baker BROS. Advisors LP purchased a new position in shares of Ionis Pharmaceuticals in the third quarter valued at $8,952,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.